Related Experiment Video
Updated: May 16, 2026
Evaluation of Stem Cell Therapies in a Bilateral Patellar Tendon Injury Model in Rats
Published on: March 30, 2018
Systematic review and meta-analysis of mesenchymal stem/stromal cells therapy for impaired renal function in small
Yan Wang1, Juan He, Xiaohua Pei
1Department of Geriatrics, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Aim:
The meta-analysis of recent small animal experiments of mesenchymal stem/stromal cells (MSC) therapy for impaired kidney could provide significant clues to design large animal experiments as well as human clinical trials.
Method:
A total of 21 studies was analyzed. These, were indexed from PubMed and Embase databases. All data were analyzed by RevMan 5.1 and SPSS 17.0. Pooled analysis and multivariable meta-regression were calculated by random effects models. Heterogeneity and publication bias across the studies were also explored.
Results:
Pooled analysis showed elevated serum creatinine (Scr) reduction in the animal models of renal failure following MSC therapy. By exploratory multivariable meta-regression, significant influence factors of Scr reduction were the time point of Scr measurement (early measurement showed greater reduction than the late (P = 0.005)) and the route of MSC delivery (arterial delivery of MSCs caused greater reduction in elevated Scr, when compared with the intra-renal delivery and intravenous injection (P = 0.040)). Subgroup analysis showed there tended to be greater reduction in Scr with higher MSC number (>10(6)), the renal ischemia-reperfusion injury (IRI) model, and late administration (>1 day) after injury.
Conclusion:
The present meta-analysis confirmed that MSC therapy could improve impaired renal function. MSCs might get obvious effect in the early stage of renal injuries after arterial delivery. Further, this meta-analysis may provide important clues for animal experiments even for human clinical trials in MSC studies.
Insights
Mesenchymal stem/stromal cell (MSC) therapy shows promise in improving kidney function in animal models. Early arterial delivery of MSCs appears most effective for reducing serum creatinine in renal failure.
Area of Science:
- Regenerative Medicine
- Nephrology
- Stem Cell Biology
Background:
- Mesenchymal stem/stromal cells (MSCs) are being investigated for their therapeutic potential in kidney diseases.
- Previous small animal studies suggest MSC therapy may improve renal function.
- A comprehensive analysis is needed to guide future large animal and human clinical trials.
Purpose of the Study:
- To meta-analyze recent small animal experiments on MSC therapy for impaired kidney function.
- To identify factors influencing the efficacy of MSC therapy in renal failure models.
- To provide evidence-based insights for designing future preclinical and clinical studies.
Main Methods:
- Systematic review and meta-analysis of 21 studies from PubMed and Embase.
- Data analyzed using RevMan 5.1 and SPSS 17.0 with random effects models.
- Exploratory multivariable meta-regression, heterogeneity, and publication bias were assessed.
Main Results:
- Pooled analysis demonstrated a reduction in serum creatinine (Scr) following MSC therapy in renal failure models.
- Early Scr measurement (P=0.005) and arterial MSC delivery (P=0.040) were associated with greater Scr reduction.
- Higher MSC numbers (>10^6), renal ischemia-reperfusion injury (IRI) models, and late administration (>1 day) showed trends towards improved outcomes.
Conclusions:
- MSC therapy is confirmed to improve impaired renal function in animal models.
- Optimal therapeutic effects may be achieved with early administration via arterial delivery.
- Findings offer critical guidance for the design of future MSC-based animal experiments and human clinical trials.
Related Concept Videos
01:19Mesenchymal Stem Cells
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...